Laboratory Information Systems Lis MarketSize, Share & Industry Analysis, 2026-2034By TypeBy Delivery ModeBy ComponentBy ApplicationBy Organization Size

A laboratory information system is software, delivered either as a standalone platform or integrated into a hospital's electronic health record, that manages the receipt, tracking, testing workflow, quality control and reporting of laboratory samples and results. It is bought by clinical diagnostic laboratories, hospital and health-system laboratories, anatomical pathology laboratories, blood banks and molecular diagnostic laboratories that need to manage sample chain of custody, instrument interfacing and regulatory reporting at scale. Buyers range from large hospital-network laboratory departments to small independent and reference laboratories, each selecting a deployment mode and level of integration suited to their sample volume and IT resources.

The global laboratory information systems lis market stood at USD 2.75 billion in 2025. A forecast-period rate of 8.04% takes it to USD 5.55 billion by 2034, and the study reports every year in between, passing USD 1.75 billion in 2020, USD 2.54 billion in 2024, USD 2.99 billion in 2026 and USD 4.11 billion in 2030.

52% of 2025 revenue sits in Standalone LIS, worth USD 1.43 billion and rising to USD 2.33 billion at 41.98% by 2034, the largest type line in both years. Growth is fastest in Integrated LIS at 10.3% and slowest in Standalone LIS at 5.49%. Integrated LIS take share over the period; Standalone LIS give it up while still growing in absolute terms.

Cut by delivery mode, the largest line is On-premise LIS: 38.18% of 2025 revenue, worth USD 1.05 billion, and 21.98% at USD 1.22 billion by 2034. Cloud-based LIS grows faster at 13.46% against 1.53%, moving from 34.91% of revenue to 54.95% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views, not components.

North America is the largest region at 41.1% of 2025 revenue, worth USD 1.13 billion and reaching USD 2 billion by 2034. Europe follows at 26.9%, moving from USD 0.74 billion to USD 1.39 billion, and Middle East and Africa is the smallest at 4.4%. Asia Pacific and Latin America gain share across the period, so growth is not distributed evenly between regions.

Coverage extends to five regions, two type lines and five segmentation axes over the full fifteen years. The 2025 total itself is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• A forecast-period rate of 8.04% takes the market from USD 2.75 billion in 2025 to USD 5.55 billion in 2034, against 9.46% recorded over the 2020-2025 historical period.
• The largest line by type is Standalone LIS, worth USD 1.43 billion and 52% of revenue in 2025, rising to USD 2.33 billion and 41.98% by 2034.
• Integrated LIS is the fastest-growing line at 10.3%, lifting its share from 48% in 2025 to 58.02% in 2034 and its revenue from USD 1.32 billion to USD 3.22 billion.
• Against a base case of USD 5.55 billion in 2034, the study also reports a bear case at USD 4.77 billion and a bull case at USD 6.33 billion, with the assumptions behind each set out separately.
• North America holds 41.1% of global revenue in 2025 at USD 1.13 billion, the largest of the five regions tracked, and reaches USD 2 billion by 2034.
• 87.6% of North America's base-year revenue comes from the United States alone: USD 0.99 billion in 2025, rising to USD 1.76 billion by 2034, which is why it is that region's worked example.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.

Read across the forecast period, the global laboratory information systems lis market shows movement in three places: type composition, regional weight, and the 8.04% rate applied to the whole.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; the movement is in which of them captures the revenue added.

The type mix tilts toward Integrated LIS. 10.3% against 5.49%: that gap, between Integrated LIS and Standalone LIS, is the largest on the type axis. By 2034 the two sit at 58.02% and 41.98% of revenue, against 48% and 52% in 2025. The revenue figures behind that are USD 1.32 billion to USD 3.22 billion and USD 1.43 billion to USD 2.33 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Regional weight shifts toward Asia Pacific and Latin America. Asia Pacific moves from 22.9% of revenue in 2025 to 29% in 2034, worth USD 0.63 billion rising to USD 1.61 billion; Latin America moves from 4.7% of revenue in 2025 to 5.6% in 2034, worth USD 0.13 billion rising to USD 0.31 billion. The offsetting side is North America at 41.1% moving to 36%, Europe at 26.9% moving to 25%, Middle East and Africa at 4.4% moving to 4.3%, none of which contracts. Revenue added in this market is therefore concentrating geographically instead of spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.

Fifteen years without a discontinuity. Fifteen years of revenue run USD 1.75 billion in 2020, USD 2.54 billion in 2024, USD 2.75 billion in 2025, USD 2.99 billion in 2026, USD 4.11 billion in 2030 and USD 5.55 billion in 2034. No year breaks the trajectory, and the 8.04% forecast rate compares with 9.46% recorded over 2020-2025, a continuation, not an inflection. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.

Integrated LIS carries the market's growth rate

Three sources account for the growth to 2034: 8.04% compounding across the base, share moving toward the faster type lines, and above-market expansion in the leading regions.

The bear case and what drives it

Where the forecast could be beaten

The total depends on a single line

In North America, 41.1% of global revenue puts 2025 at USD 1.13 billion with USD 2 billion projected for 2034. That makes it the first-largest region covered, in 2025 and again in 2034.

Share settles at 36% in 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the type split tracks the global one; 52% of 2025 revenue in Standalone LIS, fastest growth of 10.3% in Integrated LIS. The full report breaks North America out along every axis and by country.

87.6% of North America's base-year revenue comes from the United States; USD 0.99 billion, rising to USD 1.76 billion by 2034. At 87.6% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Set against USD 1.13 billion and USD 2 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Demand in the United States follows the type mix reported at global level: Standalone LIS is the largest line at 52% of 2025 revenue, moving to 41.98% by 2034, while Integrated LIS grows fastest at 10.3% and takes its share from 48% to 58.02%. Since 87.6% of North America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Revenue by type for the United States is reported separately in the full report.

In the United States, a Laboratory Information System is treated as regulated software when it performs functions tied to diagnostic decision-making, placing it under the Food and Drug Administration's oversight of software as a medical device. The agency's risk-based classification determines whether a given configuration needs premarket clearance or qualifies for an enforcement-discretion pathway, with interoperability and cybersecurity expectations drawn from FDA general controls and premarket guidance rather than treated as optional add-ons. A supplier must also design the system to support laboratories' own compliance obligations under the Clinical Laboratory Improvement Amendments, since the LIS is the record-keeping backbone auditors examine. Data handling further sits under the Health Insurance Portability and Accountability Act's security and privacy rules, requiring access controls, audit trails and safeguards for protected health information built into the platform rather than bolted on afterward.

Competition in the United States runs between the suppliers this study tracks: Orchard Software Corporation (US), Sunquest Information Systems (US), Cerner Corporation (US), CompuGroup Medical (Germany), Computer Programs and Systems Inc. (US), Meditech (US), SCC Soft Computer (US), Epic Systems Corporation (US), Comp Pro Med (US), American Soft Solutions Corp. (US), Allscripts Healthcare Solutions and Inc. (US) and among others.. Two different problems sit on the same axis: holding Standalone LIS at 52% of 2025 revenue, and taking Integrated LIS while it grows at 10.3%. Per-company positioning and share at country level are in the full report only.

Canada is sized at USD 0.14 billion in 2025, rising to USD 0.24 billion by 2034; 5.1% of global revenue and 12.4% of North America. It is reported separately from the United States across every segmentation axis in the full report.

In Europe, 26.9% of global revenue puts 2025 at USD 0.74 billion on the way to USD 1.39 billion by 2034. Among the five regions it ranks second by revenue in both years.

By 2034 the share stands at 25%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the type split tracks the global one; 52% of 2025 revenue in Standalone LIS, fastest growth of 10.3% in Integrated LIS. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

29.7% of Europe's base-year revenue comes from Germany; USD 0.22 billion, rising to USD 0.42 billion by 2034. It accounts for 29.7% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 0.74 billion and USD 1.39 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Germany buys along the same lines as the market globally; Standalone LIS first at 52% of 2025 revenue and 41.98% in 2034, Integrated LIS fastest at 10.3% on a share moving from 48% to 58.02%. Its 29.7% weight in Europe means those movements carry straight into the regional totals. The full report reports Germany by type separately.

In Germany, a Laboratory Information System used for reporting or interpreting diagnostic results falls within the scope of the EU In Vitro Diagnostic Regulation, since software that processes such data is itself classified as an in vitro diagnostic device. Conformity is assessed against the regulation's risk classes, with higher-risk configurations requiring notified body involvement before a CE mark can be applied, and technical documentation must demonstrate ongoing compliance rather than a one-time approval. National oversight runs through the Federal Institute for Drugs and Medical Devices, which enforces vigilance and market surveillance once a system is placed on the market. Suppliers must also satisfy German data protection law and the EU General Data Protection Regulation for handling patient results, and align with recognized quality standards for medical device software lifecycle management.

The suppliers tracked in this study (Orchard Software Corporation (US), Sunquest Information Systems (US), Cerner Corporation (US), CompuGroup Medical (Germany), Computer Programs and Systems Inc. (US), Meditech (US), SCC Soft Computer (US), Epic Systems Corporation (US), Comp Pro Med (US), American Soft Solutions Corp. (US), Allscripts Healthcare Solutions and Inc. (US) and among others.) compete in Germany across the type lines above. Standalone LIS, at 52% of 2025 revenue, is where the volume sits, and Integrated LIS, growing at 10.3%, is where position changes hands over the forecast period. A supplier weighted toward Europe is competing over a base of USD 0.74 billion in 2025 reaching USD 1.39 billion by 2034, 26.9% of global revenue at the start of that period.

The United Kingdom is sized at USD 0.18 billion in 2025, rising to USD 0.33 billion by 2034; 6.5% of global revenue and 24.3% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

4.7% of global revenue is generated in France; USD 0.13 billion in 2025, reaching USD 0.25 billion in 2034, and 17.6% of Europe.

Asia Pacific holds 22.9% of the global laboratory information systems lis market in 2025, worth USD 0.63 billion with USD 1.61 billion projected for 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

29% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 8.04%; the revenue added here is disproportionate to where the region started.

Segment composition follows the global pattern: Standalone LIS largest at 52% of 2025 revenue, Integrated LIS fastest at 10.3%. Per-axis and per-country detail for Asia Pacific sits in the full report.

33.3% of Asia Pacific's base-year revenue comes from China; USD 0.21 billion, rising to USD 0.55 billion by 2034. 33.3% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 0.63 billion in 2025 and USD 1.61 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in China follows the type mix reported at global level: Standalone LIS is the largest line at 52% of 2025 revenue, moving to 41.98% by 2034, while Integrated LIS grows fastest at 10.3% and takes its share from 48% to 58.02%. With 33.3% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-type revenue for China appears on its own in the full report.

In China, software that supports diagnostic reporting within a laboratory setting is regulated by the National Medical Products Administration as part of its medical device software framework, which distinguishes standalone diagnostic software from general hospital information tools based on its intended clinical use. A Laboratory Information System that generates or interprets test results for clinical decisions typically requires registration commensurate with its assessed risk class before it can be marketed. Suppliers must submit technical documentation addressing software verification, cybersecurity and data integrity, and must maintain conformity with national standards governing medical device software quality. Cross-border data handling and storage of patient health information are additionally subject to China's data security and personal information protection laws, which constrain how laboratory data can be transmitted or stored outside the country.

In China the field is Orchard Software Corporation (US), Sunquest Information Systems (US), Cerner Corporation (US), CompuGroup Medical (Germany), Computer Programs and Systems Inc. (US), Meditech (US), SCC Soft Computer (US), Epic Systems Corporation (US), Comp Pro Med (US), American Soft Solutions Corp. (US), Allscripts Healthcare Solutions and Inc. (US) and among others.. Volume sits in Standalone LIS at 52% of 2025 revenue; movement sits in Integrated LIS at 10.3% growth. The commercial size of that position is USD 0.63 billion in 2025 and USD 1.61 billion by 2034, 22.9% of the global total in the base year.

Japan is sized at USD 0.16 billion in 2025, rising to USD 0.42 billion by 2034; 5.8% of global revenue and 25.4% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

India is sized at USD 0.1 billion in 2025, rising to USD 0.26 billion by 2034; 3.6% of global revenue and 15.9% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

4.7% of the global laboratory information systems lis market sits in Latin America in 2025, worth USD 0.13 billion rising to USD 0.31 billion in 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

5.6% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 8.04% global rate, so this region warrants separate treatment and should not be scaled off the total.

Segment composition follows the global pattern: Standalone LIS largest at 52% of 2025 revenue, Integrated LIS fastest at 10.3%. Per-axis and per-country detail for Latin America sits in the full report.

The largest single market in Latin America is Brazil, at USD 0.07 billion in 2025 and USD 0.16 billion in 2034. 53.8% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 0.13 billion to USD 0.31 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in Brazil follows the type mix reported at global level: Standalone LIS is the largest line at 52% of 2025 revenue, moving to 41.98% by 2034, while Integrated LIS grows fastest at 10.3% and takes its share from 48% to 58.02%. Its 53.8% weight in Latin America means those movements carry straight into the regional totals. The full report reports Brazil by type separately.

In Brazil, the national health surveillance agency, Anvisa, oversees software that qualifies as a medical device, including laboratory systems whose functions extend into diagnostic interpretation rather than pure data storage. Classification follows Anvisa's risk-based rules for software as a medical device, with higher-risk functions requiring registration and demonstrated conformity with applicable technical standards before commercial distribution. A supplier must document software validation, traceability of results and mechanisms for reporting adverse events or software failures once the system is in clinical use. Handling of patient data is governed separately by Brazil's General Data Protection Law, which requires defined legal grounds for processing health information and imposes security obligations on any system storing or transmitting laboratory results.

In Brazil the field is Orchard Software Corporation (US), Sunquest Information Systems (US), Cerner Corporation (US), CompuGroup Medical (Germany), Computer Programs and Systems Inc. (US), Meditech (US), SCC Soft Computer (US), Epic Systems Corporation (US), Comp Pro Med (US), American Soft Solutions Corp. (US), Allscripts Healthcare Solutions and Inc. (US) and among others.. Standalone LIS, at 52% of 2025 revenue, is where the volume sits, and Integrated LIS, growing at 10.3%, is where position changes hands over the forecast period. A supplier weighted toward Latin America is competing over a base of USD 0.13 billion in 2025 reaching USD 0.31 billion by 2034, 4.7% of global revenue at the start of that period.

1.5% of global revenue is generated in Mexico; USD 0.04 billion in 2025, reaching USD 0.09 billion in 2034, and 30.8% of Latin America.

USD 0.12 billion of 2025 revenue is generated in Middle East and Africa, 4.4% of the global laboratory information systems lis market with USD 0.24 billion projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

By 2034 the share stands at 4.3%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

Segment composition follows the global pattern: Standalone LIS largest at 52% of 2025 revenue, Integrated LIS fastest at 10.3%. Per-axis and per-country detail for Middle East and Africa sits in the full report.

33.3% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.04 billion, rising to USD 0.08 billion by 2034. It accounts for 33.3% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 0.12 billion in 2025 and USD 0.24 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

The type pattern in Saudi Arabia is the global one: 52% of 2025 revenue in Standalone LIS, 41.98% by 2034, against 10.3% growth in Integrated LIS taking it from 48% to 58.02%. Because the country carries 33.3% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by type for Saudi Arabia is reported separately in the full report.

In Saudi Arabia, the Saudi Food and Drug Authority regulates medical device software, and a Laboratory Information System that supports diagnostic reporting can fall within this scope depending on its intended function and the clinical weight placed on its output. Suppliers seeking to market such a system typically must register the product and demonstrate conformity with recognized international standards for medical device software, often accepted through reliance on approvals already granted by reference regulators. Facilities deploying the system must also meet Ministry of Health requirements for laboratory information handling and accreditation standards that govern how patient results are recorded and retained. Data protection obligations under the country's personal data protection framework further shape how laboratory records containing patient information may be stored, accessed and transferred.

Orchard Software Corporation (US), Sunquest Information Systems (US), Cerner Corporation (US), CompuGroup Medical (Germany), Computer Programs and Systems Inc. (US), Meditech (US), SCC Soft Computer (US), Epic Systems Corporation (US), Comp Pro Med (US), American Soft Solutions Corp. (US), Allscripts Healthcare Solutions and Inc. (US) and among others. are the suppliers covered in Saudi Arabia. Two different problems sit on the same axis: holding Standalone LIS at 52% of 2025 revenue, and taking Integrated LIS while it grows at 10.3%. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.12 billion in 2025 reaching USD 0.24 billion by 2034, 4.4% of global revenue at the start of that period.

The United Arab Emirates is sized at USD 0.03 billion in 2025, rising to USD 0.06 billion by 2034; 1.1% of global revenue and 25% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, delivery mode, component, application, organization size, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.